Canada markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
51.59+1.50 (+2.99%)
At close: 04:05PM EDT
51.50 -0.09 (-0.17%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close50.09
Bid51.45 x 2200
Ask51.53 x 3100
Day's Range50.30 - 51.64
52 Week Range38.82 - 61.71
Avg. Volume25,009,375
Market Cap289.466B
Beta (5Y Monthly)0.71
PE Ratio (TTM)11.62
EPS (TTM)4.44
Earnings DateJul 28, 2022
Forward Dividend & Yield1.60 (3.19%)
Ex-Dividend DateJul 28, 2022
1y Target Est58.62
  • Reuters

    U.S. CDC backs Moderna's COVID vaccine for teens, older children

    The U.S. Centers for Disease Control and Prevention said on Friday it had recommended Moderna's COVID-19 vaccine for children and adolescents aged 6 to 17, allowing a rollout of the shots to begin for that age group. A rival vaccine from Pfizer and BioNTech, based on similar messenger RNA technology, has been available for teens for more than a year and since October for children aged 5 to 11. On Saturday, the CDC recommended Moderna's shot for children aged six months to five years, and Pfizer-BioNTech's vaccine for children aged six months to four years.

  • Business Wire

    Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts

    NEW YORK, June 24, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Thursday, July 28, 2022. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2022 Performance Report, to be issued that morning.

  • Zacks

    Novavax (NVAX) Up as EMA Recommends COVID Jab for Adolescents

    EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to Novavax's (NVAX) COVID-19 vaccine for use in adolescents. The stock rises 13.9%.